Dr. Demetri is Director of the Center for Sarcoma and Bone Oncology at Dana Farber Cancer Institute . Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center, and Executive Director for Clinical and Translational Research at the Ludwig Institute for Cancer Research. Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics Institute Physician . Professor of Medicine, Harvard Medical School .
***********************************************
Las Tres Presentaciones que Realizara J&J del Yondelis en el Congreso ASCO :
Three trabectedin abstracts have been accepted for presentation and were sponsored by Janssen and PharmaMar, a wholly owned member of the Zeltia Group:
*.- A Randomized Phase 3 Study of Trabectedin (T) or Dacarbazine (D) for the Treatment of Patients (pts) with Advanced Liposarcoma (LPS) or Leiomyosarcoma (LMS). (Abstract 10503)
Oral Abstract Session: Sarcoma. Monday, June 1 at 4:00 p.m. CDT in S504.
Lead Author: George D. Demetri, M.D., Dana-Farber Cancer Institute, Boston, Massachusetts, USA
*.- Healthcare Resource Utilization and Cost Considerations in Patients with Soft Tissue Sarcoma Treated with Chemotherapy. (Abstract 6537)
Poster Session: Health Services Research and Quality of Care. Monday, June 1 at 1:15 p.m. CDT in S Hall A.
Lead Author: Chris M. Kozma, Ph.D., CK Consulting Associates, LLC, St. Helena Island, South Carolina, USA
Trial in Progress:
*.- A Phase 3 Study of Trabectedin (T) plus Pegylated Liposomal Doxorubicin (PLD) versus PLD for Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. (Abstract TPS5606)
Poster Session: Gynecologic Cancer. Saturday, May 30 at 1:15 p.m. CDT in S Hall A.
Lead Author: Robert L. Coleman, M.D., The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
...